Benicar is a drug that is prescribed for essential arterial hypertension. In case of arterial hypertension, olmesartan causes a dose-dependent long-term reduction of a blood pressure.
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
The active ingredient of Benicar is Olmesartan – an antagonist of angiotensin II, used to treat hypertension, as well as some other diseases. Olmesartan lowers arterial pressure (has an antihypertensive effect).
Essential arterial hypertension.
For the treatment of hypertension initial and recommended dose is 10mg of Olmesartan medoxomil once a day. Maximum daily dose is 40mg of Olmesartan medoxomil. Age, gender and race does not affect dosage.
Hypersensitivity, bile duct obstruction, renal insufficiency, condition after kidney transplantation (no clinical use experience), aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, primary hyperaldosteronism, hyperkalemia, (risk of dehydration, arterial hypotension, renal failure), renal failure (Cl creatinine> 20 ml / min), chronic heart failure, bilateral stenosis of the renal arteries or stenosis of the single kidney artery, ischemic heart disease, cerebrovascular disease, age over 65 years, impaired liver function, conditions accompanied by a decrease in circulating blood volume ( including diarrhea, vomiting), as well as a diet with sodium restriction; simultaneous use with diuretics, age up to 18 years (efficacy and safety of use are not determined).
Contraindicated in pregnancy and lactation. If the pregnancy occurs during the period of treatment, use of Olmesartan medoxomil must be immediately stopped.
The following side effects were identified: vertigo, chest pain, tachycardia, abdominal pain, dyspepsia, gastroenteritis, nausea, hypercholesterolemia, arthralgia, arthritis, myalgia, rash, peripheral edema, hyperlipemia, hyperuricemia, facial edema was noticed in 5 patients taking Olmesartan medoxomil, a small decrease in hemoglobin and hematocrit, increased activity of hepatic enzymes and / or bilirubin, asthenia, vomiting, rhabdomyolysis, acute renal failure, increased creatinine level in blood, alopecia, urticaria, pruritus, angioedema.